Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Profile Name ALK fusion ALK G1202R
Gene Variant Detail

ALK fusion (unknown)

ALK G1202R (gain of function)

Relevant Treatment Approaches

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
ALK fusion ALK G1202R lung non-small cell carcinoma sensitive Lorlatinib Phase I Actionable In a Phase I trial, treatment with Lorlatinib (PF-06463922) demonstrated safety and resulted in durable responses in patients with ALK-positive non-small cell lung cancer, including patients harboring ALK G1202R (J Clin Oncol 34, 2016 (suppl; abstr 9009)). detail...
ALK fusion ALK G1202R lung non-small cell carcinoma predicted - sensitive Neladalkib Phase Ib/II Actionable In a Phase I/II trial (ALKOVE-1), Nelkarmi (neladalkib) treatment resulted in an objective response rate of 68% (32/47) in patients with ALK-positive non-small cell lung cancer harboring ALK G1202R who have received prior ALK inhibitor treatments, with duration of response over 12 mo in 80% of patients (J Clin Oncol (2026) 44 (suppl_16): 8503; NCT05384626). detail...
ALK fusion ALK G1202R lung adenocarcinoma predicted - sensitive Lorlatinib Case Reports/Case Series Actionable In a retrospective analysis, Lorbrena (lorlatinib) treatment resulted in a partial response with a progression-free survival of 3.9 months, overall survival of 12.3 months, and a duration of treatment of 4.9 months in a patient with lung adenocarcinoma harboring an ALK fusion with ALK G1202R (PMID: 39500140). 39500140
ALK fusion ALK G1202R lung non-small cell carcinoma sensitive Lorlatinib Guideline Actionable Lorbrena (lorlatinib) is included in guidelines as subsequent therapy (category 2A) for patients with advanced or metastatic non-small cell lung cancer harboring an ALK fusion with ALK G1202R (NCCN.org). detail...